BioMérieux is a specialist in the fragmented in vitro diagnostics market, with expertise in microbiology testing and syndromic molecular testing, while also active in the immunoassays market.
BioMérieux is a leader in niche markets, allowing the company to grow faster than the in vitro diagnostics market and shielding it from competing for market share with better-capitalized peers.
BioMérieux’s BioFire testing menu for molecular diagnostics is not well positioned for outpatient testing, giving competitors a chance to enter the market with more flexible testing panels.
|
Metric
|
BIM
|
BIO
|
DIA
|
|---|---|---|---|
Price/Earnings (Normalized) | 14.66 | 38.32 | 25.76 |
Price/Book Value | 2.14 | 1.33 | 2.57 |
Price/Sales | 2.30 | 3.70 | 3.54 |
Price/Cash Flow | 10.41 | 25.79 | 17.18 |
|
Metric
|
BIM
|
BIO
|
DIA
|
|---|---|---|---|
Quick Ratio | 1.44 | 2.14 | 0.81 |
Current Ratio | 2.30 | 3.14 | 1.79 |
Interest Coverage | 38.68 | 6.38 | 7.37 |
|
Metric
|
BIM
|
BIO
|
DIA
|
|---|---|---|---|
Return on Assets (Normalized) | 9.12% | 2.47% | 7.09% |
Return on Equity (Normalized) | 12.43% | 3.53% | 13.48% |
Return on Invested Capital (Normalized) | 11.31% | 2.66% | 9.39% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc
TMO
| LOCK|$>fjg@#z | LOCK|t?r | $242B | |||
| Danaher Corp
DHR
| LOCK|vHFdC%v | LOCK|kWP | $150B | |||
| Agilent Technologies Inc
A
| LOCK|fTG@hlWx | LOCK|@Kc | $47B | |||
| IQVIA Holdings Inc
IQV
| LOCK|@mDzqX | LOCK|Yh$& | $43B | |||
| Waters Corp
WAT
| LOCK|By#$>G | LOCK|>% | $42B | |||
| Illumina Inc
ILMN
| LOCK|!^l?hnB | LOCK|JXfD | $41B | |||
| IDEXX Laboratories Inc
IDXX
| LOCK|D#<%t@#n | LOCK|>@q | $41B | |||
| Mettler-Toledo International Inc
MTD
| LOCK|qw>py^g! | LOCK|#^v@W | $30B | |||
| Quest Diagnostics Inc
DGX
| LOCK|<ddCy!! | LOCK|JQw? | $26B | |||
| Labcorp Holdings Inc
LH
| LOCK|k@?TZMK& | LOCK|@>lB@ | $25B |
United States